达芦那韦/利托那韦联合利福平调整剂量的药代动力学与安全性
在病毒学抑制的HIV感染者中,将基于洛匹那韦/利托那韦的二线抗逆转录病毒治疗转换为达芦那韦/利托那韦800/100 mg q24h后,依次加入利福平并调整利托那韦和达芦那韦剂量。17/28名参与者启动研究治疗,6名(35.3%)因症状性肝炎伴严重ALT升高而退出,研究因肝毒性高发生率提前终止。仅4名完成研究;调整剂量后,q12h给药的达芦那韦谷浓度接近无利福平标准剂量,而q24h给药则明显降低。
要点
- 达芦那韦/利托那韦联合利福平调整剂量时肝毒性风险高,6/17(35.3%)因严重ALT升高退出。
- 利福平联合调整剂量达芦那韦/利托那韦时,q24h给药的达芦那韦谷浓度明显降低,q12h接近标准剂量。
- 研究因肝毒性提前终止,仅4名参与者完成全部研究阶段。
核心结论
- 达芦那韦/利托那韦调整剂量联合利福平具有不可接受的肝毒性风险。
- 每日调整剂量下达芦那韦谷浓度明显降低。
研究设计与样本
- 病毒学抑制的HIV感染者,原接受基于洛匹那韦/利托那韦的二线抗逆转录病毒治疗,转换为达芦那韦/利托那韦800/100 mg q24h。
- 依次加入利福平、上调利托那韦剂量、增加达芦那韦剂量(达芦那韦/利托那韦1600/200 mg q24h与800/100 mg q12h随机序贯联合利福平)。
- 28名参与者中17名启动研究治疗,仅4名完成研究。
主要发现
- 6名(35.3%)参与者因症状性肝炎伴严重ALT升高退出,肝毒性出现在利福平使用9-11天后及利托那韦200 mg使用2-4天后。
- 研究因肝毒性高发生率提前终止。
- 所有肝毒性在停用研究治疗后消退,所有参与者成功恢复洛匹那韦/利托那韦方案。
- 利福平联合调整剂量达芦那韦/利托那韦后,q12h给药的达芦那韦谷浓度接近无利福平标准剂量,q24h给药则未达到。
临床怎么用
- 应避免在需要利福平治疗的HIV感染者中使用调整剂量的达芦那韦/利托那韦方案。
- 接受利福平治疗的患者需密切监测肝毒性和ALT变化。
局限性
- 研究因肝毒性提前终止,仅4名参与者完成,样本量小。
- 药代动力学数据有限,无法充分评估调整剂量方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Darunavir/ritonavir is better tolerated than lopinavir/ritonavir and has a higher genetic barrier to resistance. Co-administration with rifampicin has been contraindicated as a significant reduction in darunavir exposure is expected. This is a barrier to darunavir/ritonavir use where TB is endemic. OBJECTIVES: To evaluate the safety and pharmacokinetic profile of adjusted doses of darunavir/ritonavir with rifampicin. METHODS: Virally suppressed participants on second-line lopinavir/ritonavir-based ART were switched to darunavir/ritonavir 800/100 mg q24h. In sequence: rifampicin was added; the dose of ritonavir was escalated; and darunavir was increased (darunavir/ritonavir 1600/200 mg q24h and 800/100 mg q12h were given in randomized sequence with rifampicin). Darunavir plasma concentrations were measured on the seventh/last day of each treatment period. To prevent viral rebound, dolutegravir (50 mg q12h) was added during rifampicin administration and for 1 week thereafter. Clinical events, ALT and bilirubin were monitored every 2-3 days during rifampicin administration. RESULTS: A total of 17/28 participants started study treatment. Six (35.3%) were withdrawn for symptomatic hepatitis with severe ALT elevations, developing after 9-11 days of rifampicin and 2-4 days of ritonavir 200 mg. The study was stopped prematurely due to this high rate of hepatotoxicity. Only four participants completed the study. All hepatotoxicity resolved on withdrawal of study treatment. All participants were successfully re-established on their lopinavir/ritonavir-based regimen. After doubling the darunavir/ritonavir doses on rifampicin, darunavir pre-dose concentrations approached those on standard doses without rifampicin for q12h doses, but not for q24h doses. CONCLUSIONS: Adjusted doses of darunavir/ritonavir with rifampicin had unacceptable risk of hepatotoxicity. Darunavir trough concentrations were markedly reduced with the daily adjusted dose.
引用
- Ebrahim I, Maartens G, Wiesner L, et al. Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV. J Antimicrob Chemother. 2020. PMID: 31942627. doi:10.1093/jac/dkz522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。